Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy

Por de Rooij, Martin F. M., Kuil, Annemieke, Kater, Arnon P., Kersten, Marie José, Pals, Steven T., Spaargaren, Marcel
Publicado no Blood (2015)

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia

Por de Rooij, Martin F.M., Kuil, Annemieke, Kraan, Willem, Kersten, Marie José, Treon, Steven P., Pals, Steven T., Spaargaren, Marcel
Publicado no Haematologica (2016)

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Por Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F. M., Magadala, Padmaja, Steggerda, Susanne M., Huang, Min Mei, Kuil, Annemieke, Herman, Sarah E. M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., Elias, Laurence
Publicado em 2013

N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation

Por Groen, Richard W.J., de Rooij, Martin F.M., Kocemba, Kinga A., Reijmers, Rogier M., de Haan-Kramer, Anneke, Overdijk, Marije B., Aalders, Linda, Rozemuller, Henk, Martens, Anton C.M., Bergsagel, P. Leif, Kersten, Marie José, Pals, Steven T., Spaargaren, Marcel
Publicado em 2011